Toremifene reduces fracture risk after initiation of androgen deprivation therapy

The additional study results from the Phase III clinical trial evaluating toremifene 80 mg for the prevention of fractures in men with prostate cancer on androgen deprivation therapy will be presented by GTx, Inc.at the 2010 Annual Meeting of the American Urological Association being held in San Francisco May 29-June 3.

Multivariate analysis demonstrates treatment with toremifene 80 mg reduces fracture risk after initiation of androgen deprivation therapy